Voices of IP: Peter Bradley, Innate Immunotherapeutics
Revolutionary Treatments from New Technology
Peter Bradley, Chief Business Development Officer
Auckland, New Zealand
Innate Immunotherapeutics Limited and its 8 employees are dedicated to designing and manufacturing a unique immunomodulator microparticle technology. This technology helps people with multiple sclerosis, cancers and various infectious diseases. Bradley sates that “intellectual property is pivotal” to the development of this technology and to taking their invention to the market and being able to get a return to their investors.